Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;98(12):e14924.
doi: 10.1097/MD.0000000000014924.

Prognositic significance of P-cadherin expression in breast cancer: Protocol for a meta-analysis

Yupeng Xi  1   2 , Xiwen Zhang  2 , Zizhen Yang  2   3 , Xing Zhang  1   2 , Qiujun Guo  2 , Zhenhua Zhang  1   2 , Shuntai Chen  1   2 , Honggang Zheng  2 , Baojin Hua  2
Affiliations

Prognositic significance of P-cadherin expression in breast cancer: Protocol for a meta-analysis

Yupeng Xi et al. Medicine (Baltimore). 2019 Mar.

Abstract

Background: P-cadherin is a calcium-dependent cell-cell adhesion glycoprotein. It has been implicated in invasiveness and metastasis. However, the clinical prognostic value of overexpression of P-cadherin in patients with breast cancer (BC) remains unsettled.

Methods: A systematic literature search will be performed in all available databases to quantitatively review eligible studies and identify all relevant data, which could be used to detect the relationship between overexpression of P-cadherin and overall survival (OS), disease-free survival (DFS), and clinicopathological parameters. Hazard ratio and 95% confidence intervals (CIs) or P value will be employed as effect measures to estimate the correlation between P-cadherin and the oncologic outcomes including overall survival (OS), disease-free survival (DFS). Odds ratios (ORs) and the 95% CIs will be evaluated for the pooled analysis of the correlation between P-cadherin expression and clinicopathological features. We will use the Review Manager (Revman) 5.3.5 software (Cochrane Community, London, United Kingdom) and STATA 14 software (version 14.0; Stata Corp, College Station, TX) to perform the meta-analysis to calculate the data.

Results: The review will provide a high-quality synthesis of current evidence of the prognostic role of P-cadherin in BCs. The results will be published in a peer-reviewed journal.

Conclusion: We hope that the results of this study will provide significant evidence to assess whether the expression of P-cadherin is associated with poor prognosis in patients with BC.

Prospero registration number: This meta-analysis protocol has been registered in the PROSPERO network with registration number: CRD42019119880.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of studies search and selection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30. - PubMed
    1. Anderson WF, Rosenberg PS, Prat A, et al. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst 2014;106:dju165. - PMC - PubMed
    1. Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health 2017;14: pii: E68. - PMC - PubMed
    1. Kim JY, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-kappaB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep 2016;6:31804. - PMC - PubMed